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ABSTRACT
Objective To evaluate the safety and effectiveness of
e-cigarettes, by comparing users of only e-cigarettes,
smokers of only tobacco cigarettes and dual users.
Design Prospective cohort study. We update previous
12-month ﬁndings and report the results of the
24-month follow-up.
Data sources Direct contact and questionnaires by
phone or via internet.
Methods Adults (30–75 years) were classiﬁed as: (1)
tobacco smokers, if they smoked ≥1 tobacco cigarette/day,
(2) e-cigarette users, if they inhaled ≥50 puffs/week of
any type of e-cigarette and (3) dual users, if they
smoked tobacco cigarettes and also used e-cigarettes.
Carbon monoxide levels were tested in 50% of those
declaring tobacco smoking abstinence. Hospital
discharge data were used to validate possibly related
serious adverse events in 46.0% of the sample.
Main outcome measures Sustained abstinence from
tobacco cigarettes and/or e-cigarettes after 24 months,
the difference in the number of tobacco cigarettes
smoked daily between baseline and 24 months, possibly
related serious adverse events.
Results Data at 24 months were available for 229
e-cigarette users, 480 tobacco smokers and 223 dual
users (overall response rate 68.8%). Of the e-cigarette
users, 61.1% remained abstinent from tobacco (while
23.1% and 26.0% of tobacco-only smokers and dual
users achieved tobacco abstinence). The rate (18.8%) of
stopping use of either product (tobacco and/or
e-cigarettes) was not higher for e-cigarette users
compared with tobacco smokers or dual users. Self-rated
health and adverse events were similar between all
groups. Among those continuing to smoke, there were
no differences in the proportion of participants reducing
tobacco cigarette consumption by 50% or more, the
average daily number of cigarettes and the average self-
rated health by baseline group. Most dual users at
baseline abandoned e-cigarettes and continued to
smoke tobacco. Those who continued dual using or
converted from tobacco smoking to dual use during
follow-up experienced signiﬁcant improvements in the
3 outcomes compared with those who continued or
switched to only smoking tobacco (p<0.001).
Conclusions E-cigarette use alone might support
tobacco quitters remaining abstinent from smoking.
However, dual use did not improve the likelihood of
quitting tobacco or e-cigarette use, but may be
helpful to reduce tobacco consumption. Adverse
event data were scarce and must be considered
preliminary.
Trial registration number NCT01785537.
INTRODUCTION
Despite their potential public health relevance,
the current evidence on the safety and efﬁcacy/
effectiveness of e-cigarettes is scarce, and long-term
data are urgently needed.1–7 The published pro-
spective evidence on the efﬁcacy/effectiveness for
healthy participants consists of 2 randomised
trials,8 9 2 single-arm small trials10–12 and 11 obser-
vational studies.13–23 However, these studies mostly
included users of both tobacco and e-cigarettes fol-
lowed for ≤12 months, used various assessment
methods, and did not directly compare e-cigarette
users and tobacco smokers.4 6 7 24 25 Moreover, the
entire evidence on e-cigarette safety—at 6 months
—is limited to 122 healthy participants, most of
whom were also smoking tobacco for most of the
follow-up.8 9 11 We previously reported the
12-month follow-up results26 of our 5-year study
aimed at evaluating the long-term effects of
e-cigarette use.27 We report the results of the
24-month follow-up, and include hospital dis-
charge data.
METHODS
The protocol and 12-month results of this prospect-
ive cohort study are reported elsewhere,26 27 and
registered in Clinicaltrials.gov (NCT01785537). In
brief, we recruited adults (30–75 years) who were:
(1) tobacco smokers of ≥1 tobacco cigarette daily
for ≥6 months; (2) e-cigarette users of any type of
e-cigarette for ≥6 months (3) dual users of tobacco
and e-cigarettes for ≥6 months, via general practi-
tioners, e-cigarette shops, internet advertisements
and social networks.
Data were collected through a structured ques-
tionnaire, administered through phone interview
and/or by internet, and follow-up will continue up
to 60 months. Two investigators (MEF and LM)
tested carbon monoxide levels in expired breath
(Smokerlyzer piCO+, Bedfont Scientiﬁc) in a
random sample of those declaring tobacco smoking
abstinence (25% and 50% at 12 and 24 months,
respectively).
The work was approved by Chieti University
Ethics Committee; all participants provided written
informed consent.
Outcome variables and data analysis
The primary outcome was the percentage of sus-
tained (30 days) abstinence from tobacco smoking
at 24 months. Other outcomes were the proportion
of participants abstinent from both tobacco
smoking and e-cigarette use, the number of tobacco
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cigarettes smoked per day (and the proportion of participants
reducing tobacco cigarette consumption by 50% or more
between baseline and 24 months), self-reported health (assessed
through the ﬁnal item of the Italian version of the EuroQol
EQ-D5L28) and possibly related serious adverse events. Adverse
events were both self-reported and gathered from data obtained
from the regional hospital discharge administrative database
(Italian Scheda di Dimissione Ospedaliera) for the residents in the
Abruzzo Region (46.0% of the sample); and only self-reported
for the rest of the sample. The details of the International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) codes used to extract adverse events are reported in
the protocol27 and in the online supplementary material.
The differences by baseline cigarette use were evaluated using
Kruskal-Wallis or one-way analysis of variance with Sidak cor-
rection for continuous variables, and χ2 test for categorical vari-
ables. For the latter, when more than two categories were
compared (such as for cigarette use), separate comparisons were
made for one group versus the others, and different p values
were computed. The difference in continuous variables (ie,
number of cigarettes smoked per day) within groups between
baseline and end of follow-up was evaluated through Wilcoxon
matched-pairs signed-rank test.
Multivariable random-effect linear and logistic regressions,
with geographical region as the cluster unit, were used to in-
vestigate potential predictors of continuous and categorical
outcomes, respectively. We set eight multivariable models for
the following outcomes: (A) tobacco smoking abstinence at
24 months; (B) abstinence from both tobacco smoking and
e-cigarette use at 24 months; (C) possibly related serious
adverse events at 24 months; (D) reduction by ≥50% of tobacco
cigarette consumption from baseline to 24 months, by baseline
cigarette use group (this model was ﬁtted into two versions: the
ﬁrst included the whole sample of tobacco and dual users at
baseline; the second included only the subsample of continuing
smokers, excluding those who had quit and whose cigarette con-
sumption was zero at follow-up); (E) reduction by ≥50% of
tobacco cigarette consumption from baseline to 24 months, by
24-month cigarette use group (as most dual users switched
to another group, this model and model G were needed to
further investigate the potential predictors of tobacco smoking
reduction among the switchers); (F) difference in the daily
number of tobacco cigarettes smoked per day at 24 months
compared with baseline, by baseline cigarette use group (this
model was ﬁtted into two versions: the ﬁrst included the
whole sample of tobacco and dual users at baseline; the second
included only the subsample of continuing smokers, excluding
those who had quit and whose cigarette consumption was zero
at follow-up); (G) difference in the daily number of tobacco
cigarettes smoked per day at 24 months compared with base-
line, by 24-month cigarette use group and (H) difference in
the self-rated health at 24 months compared with baseline.
The users of e-cigarettes only at baseline were excluded from
models D, E, F and G.
With the exceptions of models C, E and G, which included a
limited number of successes and had to be ﬁtted with a
restricted set of covariates, for all other models the number of
successes of categorical outcomes (excluding adverse events)
approximated 10 successes for each recorded variable (thus
avoiding overﬁtting requirements).29 It was thus decided a priori
to include all recorded variables into all ﬁnal models regardless
of signiﬁcance, unless inclusion would create multicollinearity
or violate other assumptions. Each covariate was tested in its
original form or transformed if needed: only the number of
cigarettes smoked per day was transformed into its square root;
because the results were similar to those with the covariate
included in its untransformed version, it was thus kept in the
model in its original form. Models A, B, D, F and H were
adjusted for the following baseline characteristics: age, gender,
body mass index, marital status, educational level, occupation,
alcohol use, hypertension, hypercholesterolaemia, diabetes, self-
rated health and years of tobacco smoking (former smoking for
e-cigarette-only users). We excluded physical activity from the
ﬁnal multivariate models due to substantial missing data (n=41)
and its virtually null effect on any dependent variables. The
number of tobacco cigarettes smoked per day was transformed
to be included into models A, B, C and H: because no tobacco
cigarettes were smoked at baseline by e-cigarette-only users, we
recategorised the amount of smoking, using tertiles. Those
smoking <10 tobacco cigarettes per day (or <50 puffs per day
if e-cigarette-only smokers) at baseline were assigned to the
lowest tertile of consumption; smokers of 10–19 tobacco cigar-
ettes (or 50–100 puffs if e-cigarette-only users) per day at base-
line were assigned to the intermediate tertile; smokers of 20 or
more cigarettes (or 100 or more puffs if e-cigarette-only users)
per day at baseline were classiﬁed into the highest tertile.
Potential interactions with the dependent variable and/or
quadratic/cubic terms were investigated for all covariates. In
logistic regression analyses, the outlier analysis was based on
Pearson calculation and standardised residuals, the change in
Pearson χ2, and Dbeta inﬂuence statistics and leverage (hat diag-
onal matrix). The validity of the ﬁnal linear regression models
was assessed as follows. The assumption of constant error vari-
ance was checked graphically, plotting Pearson residuals versus
ﬁtted values, and formally, using the Cook-Weisberg test for
heteroscedasticity. High leverage observations were identiﬁed by
computing Pearson, standardised and studentised residuals,
Cook’s D inﬂuence, Welsch distance and the hat diagonal
matrix (LC Hamilton. Statistics with Stata: Version 12, Eighth
Edition. Boston: Cengage 2013). We found <30 inﬂuential or
high-leverage observations in all models. In all cases, we
repeated the analyses excluding these observations, with no sub-
stantial changes, and we thus kept all observations in the
models.
We had very few missing data for all outcome variables (<5)
except self-rated health, which was not answered by 56 partici-
pants at baseline (but only 30 of them were kept in the
24-month assessment), and by 3 participants at the 24-month
follow-up. Models A, B, C and H were rerun without self-rated
health at baseline (−30 participants), with no appreciable vari-
ation, therefore it was retained. Model H was inevitably ﬁtted
with 33 missing observations. Given that the participants lost in
model H were relatively few (3.5% of the sample) and balanced
across baseline groups, no missing data imputation technique
was adopted. Finally, the distribution of the difference in self-
rated health was relatively skewed (Shapiro-Wilk p<0.01) and
model G was set also using its cubic form. However, again the
estimates of p values of cigarette use covariates were similar and
the dependent variable was maintained in its original form to
facilitate results interpretation.
The results of the logistic regression analyses are presented as
ORs and the corresponding 95% CIs whereas the results of the
linear regression analyses are presented as β-coefﬁcients and
95% CIs. A two-tailed p value of 0.05 was considered signiﬁ-
cant for all analyses, which were performed using Stata V.13.1
(Stata Corp, College Station, Texas, USA, 2014).
2 Manzoli L, et al. Tob Control 2016;0:1–9. doi:10.1136/tobaccocontrol-2015-052822
Research paper
group.bmj.com on June 7, 2016 - Published by http://tobaccocontrol.bmj.com/Downloaded from 
RESULTS
The ﬂow of the participants is shown in ﬁgure 1 and baseline
characteristics are reported in online supplementary table S1.
After 24 months, 61.1% of the 229 baseline e-cigarette-only
users were still abstinent from tobacco smoking; 23.1% of
the 480 baseline tobacco smokers and 26.0% of the 223 base-
line dual users achieved tobacco abstinence (p<0.001 for
e-cigarette-only users vs tobacco smokers or dual users; table 1).
The proportion of participants who achieved complete abstin-
ence (who were using neither tobacco cigarettes nor e-cigarettes)
did not signiﬁcantly differ by baseline use group: 18.8%, 17.5%
and 14.3% among e-cigarette users, tobacco smokers and dual
users, respectively (all p>0.05).
The proportion of participants reducing tobacco cigarette
consumption by 50% or more, or by ≥5 tobacco cigarettes per
day, and the average daily number of cigarettes, did not change
by baseline group (table 1; all p>0.05). Importantly, the major-
ity (83.4%) of dual users at baseline abandoned e-cigarettes and
continued to smoke only tobacco (57.4%), or quit tobacco
(11.7%) or both tobacco cigarettes and e-cigarettes (14.3%)
during follow-up (table 1). Therefore, a second analysis was
conducted stratifying by baseline and 24-month cigarette use, in
order to assess the variation of the pattern of consumption
among the switchers as well. Among the 603 tobacco-only
smokers or dual users at baseline, 21 of the 40 (52.5%) partici-
pants who started or continued dual use during the follow-up
reduced tobacco cigarette consumption by ≥50%, while only 67
of the 489 (13.7%) participants who started or continued only
tobacco smoking showed a ≥50% cigarette reduction (p<0.001,
table 1).
No signiﬁcant differences in average self-rated health were
noted by baseline group (all p>0.05). A substantial improve-
ment, however, was observed for tobacco smokers or dual users
who switched to e-cigarettes only (+1.1 or 1.0 in EuroQol
mean score, respectively; p<0.05; table 1).
We recorded an identical number of mouth irritations (n=38)
and possibly related serious adverse events (n=38; table 1).
Potential adverse events were reported by 4.4%, 2.9% and
6.3% of baseline e-cigarette users, tobacco smokers and dual
users, respectively (p<0.05 for the comparison of tobacco
smokers vs dual users). Mouth irritation rates were 6.1%, 4.2%
and 1.8% in the above groups (p<0.05 for the comparison of
e-cigarette users vs dual users). The distribution of adverse
events by baseline and 24-month group is reported in ﬁgure 1.
The characteristics of the participants reporting a serious
adverse event, and its type, are reported in online supplemen-
tary table S2. Also, the cigarette use throughout the follow-up
of the 38 participants experiencing a possibly related serious
adverse event is shown in online supplementary ﬁgure S1.
Notably, most tobacco-only smokers at baseline, who experi-
enced an adverse event, remained tobacco-only smokers or quit
both tobacco smoking and e-cigarette use. In contrast, most of
the e-cigarette-only and dual users at baseline who experienced
a serious adverse event (n=24), switched group during the
24-month follow-up: 13 switched to tobacco smoking only, and
5 quit both tobacco cigarettes and e-cigarettes.
Multivariate analyses substantially conﬁrmed univariate
results (table 2): when several potential confounders were
adjusted for, tobacco smoking abstinence remained signiﬁcantly
more likely among e-cigarette users (adjusted OR 5.56; 95% CI
3.89 to 7.95; p<0.001); the likelihood of abstinence from
tobacco smoking and e-cigarette use, as well as self-reported
health, did not signiﬁcantly vary by baseline group (p>0.05);
the probability of halving or reducing the average number of
daily tobacco cigarettes smoked did not change by baseline
group, but tobacco smokers who started dual use or dual users
Figure 1 Flow of the participants, number of quitters and possibly related serious adverse events.
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Table 1 Main outcomes at 24 months
Cigarette use at baseline
E-cigarettes only Tobacco cigarettes only Dual use
(n=229) (n=480) (n=223) p ValueA p ValueB p ValueC
1. Cigarette use at 24 months
Tobacco cigarettes only, per cent (n)
Continuous tobacco abstinence from baseline or cessation from tobacco
smoking during follow-up*
61.1 (140) 23.1 (111) 26.0 (58) <0.001 0.4 <0.001
Tobacco smoking (continued or relapsed) 38.9 (89) 76.9 (369) 74.0 (165) <0.001 0.4 <0.001
All product use (cigarettes and/or e-cigarettes), per cent (n)
Quit using any product (either tobacco and/or e-cigarette) 18.8 (43) 17.5 (84) 14.3 (32) 0.7 0.3 0.20
Using e-cigarettes only 42.4 (97) 5.6 (27) 11.7 (26) <0.001 0.004 <0.001
Dual use (tobacco cigarettes and e-cigarettes) 8.3 (19) 1.3 (6) 16.6 (37) <0.001 <0.001 0.007
Smoking tobacco cigarettes only 30.6 (70) 75.6 (363) 57.4 (128) <0.001 <0.001 <0.001
2. Number of tobacco cigarettes
Mean number of tobacco cigarettes daily at 24 months (SD)
Stratified by baseline group – 10.0 (8.4) 11.2 (9.8) – 0.09 –
Stratified by cigarette use at 24 months
Started or continued tobacco cigarettes only 0.0 (0.0) 14.8 (8.1) 15.8 (9.1) – 0.2 –
Started or continued dual use only 0.0 (0.0) 19.0 (6.3) 14.0 (9.5) – 0.2 –
(p=0.2)† (p=0.3)‡
Percentage of participants reducing tobacco cigarettes of 50% or more from baseline to 24 months
Stratified by baseline group – 34.5 39.7 – 0.2 –
Stratified by product use at 24 months
Started or continued tobacco cigarettes only – 14.1 (n=51) 9.4 (n=12) – 0.2 –
Started or continued dual use only – 66.7 (n=4) 50.0 (n=17) – 0.5 –
(p<0.001)† (p<0.001)‡
Percentage of participants who smoked ≥5 tobacco cigarettes less between baseline and 24 months
Stratified by baseline group – 38.6 42.5 – 0.3 –
Stratified by product use at 24 months
Started or continued tobacco cigarettes only – 23.5 (n=85) 22.1 (n=28) – 0.7 –
Started or continued dual use only – 66.7 (n=4) 55.9 (n=19) – 0.6 –
Mean difference in the daily number of tobacco cigarettes between 24 months and baseline (SD)
Stratified by baseline group – −4.1 (8.1) −4.0 (11.8) – 0.9 –
Stratified by product use at 24 months
Started or continued tobacco cigarettes only – −1.6 (6.4) −0.8 (9.6) – 0.2 –
Started or continued dual use only – −5.3 (3.3) −6.5 (10.7) – 0.8 –
(p=0.2)† (p=0.003)‡
3. Self-rated health§–Mean difference between 24 months and baseline (SD)
Stratified by baseline group 0.0 (1.7) 0.0 (1.4) −0.1 (1.7) 0.9 0.4 0.5
Stratified by product use at 24 months
Quit using any product (either tobacco and/or e-cigarette) +0.2 (1.6) +0.3 (1.4) −0.2 (2.1) 0.7 0.14 0.4
Using e-cigarettes only +0.3 (1.4) +1.1 (1.7) +1.0 (1.6) 0.014 0.8 0.03
Dual use (tobacco cigarettes and e-cigarettes) −0.3 (1.7) +0.3 (1.5) +0.2 (1.7) 0.4 0.9 0.3
Smoking tobacco cigarettes only −0.5 (1.9) −0.1 (1.4) −0.4 (1.4) 0.041 0.039 0.7
4. Safety—possibly related sAEs, per cent (n)
Stratified by baseline group
Mouth irritation 6.1 (14) 4.2 (20) 1.8 (4) 0.27 0.10 0.019
Continued
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who continued dual using, were signiﬁcantly more likely to
halve their tobacco cigarette consumption and to decrease the
average number of cigarettes per day than those who started or
continued only smoking tobacco (all p<0.001); dual users at
baseline remained signiﬁcantly more likely to report a serious
adverse event than tobacco-only smokers (OR 2.40; 95% CI
1.09 to 5.26; p=0.029).
Switching or quitting cigarette use
Overall, 435 participants switched (n=276; 29.6%) or stopped
(n=159; 17.1%) using either product (tobacco cigarettes or
e-cigarettes) during the follow-up (ﬁgure 1 and table 3). Very
few tobacco cigarette smokers switched to dual use (5.6%) or
to e-cigarettes only (1.3%). In contrast, only 16.6% of dual
users remained dual users after 24 months, and most of them
(57.4%) abandoned e-cigarettes and continued to smoke only
tobacco cigarettes. Thirty-nine per cent of e-cigarette-only users
switched to tobacco smoking, while 42.4% continued with e-
cigarettes only or stopped using either tobacco cigarettes or
e-cigarettes.
Of the 159 participants who quit using either product at
24 months, 91 had quit at the 12-month follow-up (57.2%). Of
the 131 participants who quit using either product at 12 months,
6 were lost to follow-up, 91 remained abstinent and 34 relapsed
(27.2%): 29 to tobacco smoking only, 4 to e-cigarettes only and
1 to dual use. Similar results were observed for quitting tobacco
cigarettes (table 3).
Other secondary ﬁndings on CO levels, the other predictors
of tobacco smoking, and abstinence from tobacco cigarettes and
e-cigarettes, and adverse events, are reported in the online sup-
plementary material.
DISCUSSION
To date, this is the only study to directly compare smokers of
tobacco cigarettes only with users of e-cigarettes only, and to
provide safety data on e-cigarette-only users for >12 months.
With respect to the ﬁrst year of follow-up, the analyses after the
second year provided some important conﬁrmations and some
new insights.
This conﬁrms that complete switching to e-cigarettes may
help tobacco quitters remain abstinent from smoking: after
24 months the rate of relapse to tobacco smoking remained
relatively low (38.9%), if compared with the 60–90% relapse
rates of tobacco cigarette smokers observed in population-based
studies.30 It should be kept in mind that all e-cigarette users in
our sample were former tobacco smokers at baseline, with a
mean time of 8 months since switching to e-cigarettes. Notably,
the analysis of those who had quit tobacco smoking at
12 months showed that the relapse rates to tobacco smoking at
24 months were also relatively low for tobacco-only smokers
(30.3%; table 3). With regard to safety, the rate of adverse
events was not lower in e-cigarette-only users than in tobacco
smokers, which was expected in this phase of the study, given
that the excess risk of tobacco smoking takes 1–5 years to sub-
stantially decrease.31 32
The results also conﬁrmed that the use of e-cigarettes in add-
ition to tobacco smoking (dual use) does not seem to encourage
tobacco smokers to quit tobacco. Further, dual users at baseline
did not differ from tobacco-only smokers in tobacco cigarette
consumption and self-rated health. However, the vast majority
of dual users switched to another use status during the
follow-up, which suggests that dual use is generally a transient
phase rather than a long-term pattern of use. Further, the
analyses stratiﬁed by baseline status may provide limited
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Table 2 Tobacco smoking and/or e-cigarette use abstinence or cessation, possibly related adverse events, difference in daily tobacco cigarette consumption and self-reported health: results of the
multivariate analyses
Outcomes at 24 months Adjusted OR (95% CI) p Value Crude OR (95% CI) p Value
Continuous tobacco abstinence from baseline or quit tobacco smoking during follow-up*,†
Tobacco cigarettes only at baseline 1 (ref cat) – 1 (ref cat) –
E-cigarettes only at baseline 5.56 (3.89 to 7.95) <0.001 5.23 (3.72 to 7.35) <0.001
Both tobacco and e-cigarettes at
baseline
1.25 (0.85 to 1.84) 0.2 1.17 (0.81 to 1.69) 0.4
Quit all cigarettes (electronic and/or traditional)*
Tobacco cigarettes only at baseline 1 (ref cat) – 1 (ref cat) –
E-cigarettes only at baseline 1.12 (0.73 to 1.72) 0.6 1.09 (0.73 to 1.64) 0.7
Both tobacco and e-cigarettes at
baseline
0.94 (0.59 to 1.49) 0.8 0.79 (0.51 to 1.23) 0.3
Safety–possibly related sAEs‡
Tobacco cigarettes only at baseline 1 (ref cat) – 1 (ref cat) –
E-cigarettes only at baseline 1.48 (0.63 to 3.47) 0.4 1.52 (0.66 to 3.48) 0.3
Both tobacco and e-cigarettes at
baseline
2.40 (1.09 to 5.26) 0.029 2.23 (1.04 to 4.76) 0.038
Reduction of tobacco cigarette consumption by 50% or more from baseline to 24 months§
Tobacco cigarettes only at baseline 1 (ref cat) – 1 (ref cat) –
Both tobacco and e-cigarettes at
baseline
1.28 (0.90 to 1.82)¶ 0.2 1.25 (0.89 to 1.76)¶ 0.2
0.99 (0.57 to 1.71)** 0.9 1.25 (0.76 to 2.05)** 0.4
Reduction of tobacco cigarette consumption by 50% or more from baseline to 24 months††
Tobacco or dual users at baseline
who switched to or continued with
tobacco smoking only
1 (ref cat) – 1 (ref cat) –
Tobacco or dual users at baseline
who started or continued dual use
8.48 (4.05 to 17.8) <0.001 7.47 (3.81 to 14.7) <0.001
Adjusted coefficient (95% CI) Raw coefficient (95% CI)
Difference in the daily number of tobacco cigarettes from 24 months to baseline‡‡
Tobacco cigarettes only at baseline 0 (ref cat) – 0 (ref cat) –
Both tobacco and e-cigarettes at
baseline
0.44 (−0.88 to 1.75)¶ 0.5 0.10 (−1.41 to 1.61)¶ 0.9
0.75 (−1.13 to 2.63)** 0.4 0.87 (−0.42 to 2.15)** 0.2
Difference in the daily number of tobacco cigarettes from 24 months to baseline§§
Tobacco smokers who continued
only smoking and dual users at
baseline who switched to tobacco
only smoking
0 (ref cat) – 0 (ref cat) –
Dual users at baseline who
continued dual use and
tobacco-only smokers who
switched to dual use
−5.71 (−8.02 to −3.39) <0.001 −5.32 (−7.80 to −2.85) <0.001
Difference in the self-reported health score from 24 months to baseline¶¶
Tobacco cigarettes only at baseline 0 (ref cat) – 0 (ref cat) –
E-cigarettes only at baseline 0.14 (−0.08 to 0.35) 0.2 −0.03 (−0.27 to 0.22) 0.8
Continued
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inform
ation
on
dual
users.
H
ow
ever,
w
hen
baseline
and
24-m
onth
use
data
w
ere
considered
together,
w
e
found
that
tobacco-only
sm
okers
w
ho
started
dual
use
or
dual
users
w
ho
continued
dual
use
w
ere
signiﬁcantly
m
ore
likely
to
reduce
the
average
num
ber
of
daily
cigarettes,
to
reduce
their
consum
ption
by
50%
or
m
ore,
and
show
ed
a
signiﬁcant
increase
in
self-rated
health
at
24
m
onths
com
pared
w
ith
those
w
ho
returned
to
or
continued
sm
oking
only
tobacco.
Sim
ilarly,
w
hile
baseline
dual
users
show
ed
a
signiﬁcantly
higher
probability
of
a
serious
adverse
event,
all
these
events
occurred
in
participants
w
ho
sw
itched
group
during
the
24-m
onth
follow
-up:
six
stopped
sm
oking
(tw
o
of
w
hom
continued
using
e-cigarettes)
and
eight
returned
to
only
sm
oking
cigarettes.
M
oreover,
it
cannot
be
excluded
that,
particularly
for
those
w
ho
returned
to
only
sm
oking
tobacco,
the
previous
years
of
exposure
to
sm
oking
(23
years
on
average
in
our
sam
ple)
played
a
greater
role
in
developing
an
adverse
health
outcom
e
beyond
the
1-year
(n=
4)
or
2-year
(n=
4)
periods
of
dualuse.
O
ur
ﬁndings
on
sm
oking
cessation
and
reduction
rates
are
com
parable
to
som
e
previous
studies, 1
0
1
4
1
6
1
8
2
0
3
3
but
differ-
ent
from
others. 1
1
1
3
1
5
1
7
1
8
3
3
A
s
a
potential
explanation,
three
of
the
latter
studies
m
ay
have
had
less
m
otivated
sam
ples, 9
1
1
1
7
and
another
included
som
e
countries
w
ith
an
e-cigarette
ban,
w
hich
could
affect
use
patterns. 1
3
O
ur
relapse
rate
to
tobacco
sm
oking
am
ong
e-cigarette
users
doubled
the
estim
ate
by
E
tter
and
B
ullen
1
6
(w
hose
sam
ple,
how
ever,
m
ay
have
been
highly
m
otivated
to
m
aintain
abstinence
from
sm
oking
as
they
w
ere
recruited
from
sm
oking
cessation
w
eb-
sites),
but
w
as
m
uch
low
er
than
the
≅
94%
relapse
rate
in
the
random
ised
controlled
trial
by
B
ullen
et
al. 8
H
ow
ever,
our
observational
study
included
e-cigarette
users
w
ho
w
ere
already
abstinent
from
tobacco
sm
oking
for
m
any
m
onths
prior
to
recruitm
ent,
did
not
control
for
type
of
e-cigarette
used
and
had
broader
inclusion
criteria
than
som
e
other
studies
(eg,
included
sm
okers
of
<
10
cigarettes
per
day).
Som
e
of
our
study
lim
itations
have
already
been
reported
in
detail
elsew
here. 2
6
In
brief,
sm
oking
cessation
w
as
partially
self-
reported.
H
ow
ever,
w
e
tested
C
O
levels
in
50%
of
the
sam
ple
in
the
24-m
onth
follow
-up,
ﬁnding
false
declarations
w
ere
spor-
adic
(n=
1
am
ong
e-cigarette
users;
n=
2
am
ong
tobacco
sm
okers).
Second,
w
e
had
no
24-m
onth
follow
-up
data
for
31.2%
of
baseline
participants.
H
ow
ever,
the
loss
rate
is
still
low
er
than
those
in
m
ost
previous
prospective
studies, 9
1
1
1
4
1
6
–1
8
and
non-responders
w
ere
sim
ilar
to
responders
for
m
ost
baseline
variables. 2
6
T
hird,w
e
did
not
distinguish
betw
een
different
types
of
e-cigarettes
used,
and
could
not
reliably
assess
frequency
of
use.
T
hese
factors
(product
type
and
frequency
of
use)
appear
to
be
im
portant
characteristics
predicting
change
in
sm
oking
behav-
iour. 1
4
1
9
2
0
Finally,
it
has
been
suggested
that
dual
users
are
fre-
quently
‘quitting
failures’
and
thus
biased
against
cessation. 6
H
ow
ever,
in
our
sam
ple,
the
proportion
of
those
w
ho
tried
quit-
ting
before
w
as
quite
sim
ilar
betw
een
tobacco
sm
okers
(33.7%
)
and
dualusers
(35.9%
).
CO
N
CLU
SIO
N
S
O
verall,
the
ﬁrst
2
years
of
the
study
con
ﬁrm
that
sw
itching
com
pletely
to
e-cigarettes
m
ight
help
tobacco
sm
okers
rem
ain
abstinent
from
sm
oking.T
he
ﬁndings
on
dualuse
of
e-cigarettes
and
tobacco
sm
oking
rem
ain
controversial:
dual
use
did
not
im
prove
the
likelihood
of
quitting
tobacco
or
use
of
e-cigarettes,
but
it
m
ay
facilitate
the
reduction
of
tobacco
cigarette
consum
p-
tion
and
im
prove
self-rated
health.
D
ualuse
also
did
not
appear
to
reduce
sm
oking
quit
rates
com
pared
w
ith
those
of
sm
okers
not
using
e-cigarettes.
A
dverse
events
w
ere
still
scarce,
and
the
Table 2 Continued
Adjusted coefficient (95% CI) Raw coefficient (95% CI)
Both tobacco cigarettes and
e-cigarettes at baseline
−0.15 (−0.36 to 0.07) 0.2 −0.14 (−0.38 to 0.11) 0.3
*Random-effect logistic regression with region as the cluster level, adjusting for the following baseline characteristics: age, gender, BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolaemia, diabetes, self-reported
health, years of tobacco smoking (former smoking for e-cigarette users), number of tobacco cigarettes smoked per day (or puffs per day for e-cigarette only smokers). A total of 902 participants were included in the final model due to 30 missing items in
the self-reported health item at baseline.
†Including (1) users of e-cigarettes only at baseline who quit e-cigarette use and did not start tobacco smoking; (2) smokers of tobacco cigarettes only at baseline who quit tobacco cigarette use and did not start e-cigarette use; (3) dual users at baseline
who quit both tobacco smoking and e-cigarette use; (4) e-cigarette users at baseline who continued to use only e-cigarettes; (5) tobacco cigarettes smokers at baseline who quit tobacco smoking and started using e-cigarettes; (6) dual users at baseline
who quit tobacco smoking and continued to use e-cigarettes only.
‡Random-effect logistic regression with region as the cluster level, adjusting for age, baseline self-reported health and quitting all smoking during the 24-month follow-up.
§E-cigarette-only users at baseline were not included. Random-effect logistic regression with region as the cluster level, adjusting for the following baseline characteristics: age, gender, BMI, marital status, educational level, occupation, alcohol use,
hypertension, hypercholesterolaemia, diabetes, self-reported health, years of tobacco smoking, number of tobacco cigarettes smoked per day. A total of 682 participants were included in the final model due to 21 missing items in the self-reported health
item at baseline.
¶Computed from a model that included the whole sample of tobacco and dual smokers at baseline.
**Computed from a model that included only the subsample of baseline smokers who continued smoking at 24 months (excluding those who had quit and whose cigarette consumption was zero at follow-up).
††Restricted to tobacco only smokers or dual users at baseline who did not quit or switch to e-cigarettes only (n=529). Random-effect logistic regression with region as the cluster level, adjusting for the following baseline characteristics: age, gender,
self-reported health, years of tobacco smoking, number of tobacco cigarettes smoked per day.
‡‡E-cigarette-only users at baseline were not included. Random-effect linear regression with region as the cluster level, adjusting for the following baseline characteristics: age, gender, BMI, marital status, educational level, occupation, alcohol use,
hypertension, hypercholesterolaemia, diabetes, self-reported health, years of tobacco smoking, number of tobacco cigarettes smoked per day. A total of 682 participants were included in the final model due to 21 missing items in the self-reported health
item at baseline.
§§Restricted to tobacco-only smokers or dual users at baseline who did not quit or switch to e-cigarettes only (n=529). Random-effect linear regression with region as the cluster level, adjusting for the following baseline characteristics: age, gender,
self-reported health, years of tobacco smoking, number of tobacco cigarettes smoked per day.
¶¶Random-effect linear regression with region as the cluster level, adjusting for the following baseline characteristics: age, gender, BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolaemia, diabetes, self-reported
health, years of tobacco smoking (former smoking for e-cigarette users), number of tobacco cigarettes smoked per day (or puffs per day for e-cigarette only smokers). A total of 899 participants were included in the final model due to 30 missing items in
the self-reported health item at baseline and 3 missing items in the self-reported health at 24 months.
BMI, body mass index; sAEs, serious adverse events.
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next years of follow-up will help clarify safety concerns, which
remain the most important issue to support policies on
e-cigarettes use.
What this paper adds
▸ Despite the potential public health relevance, the current
evidence on long-term safety and efﬁcacy/effectiveness of
e-cigarettes is scarce and conﬂicting.
▸ After 24 months of a prospective follow-up, most users of
e-cigarettes alone were able to remain abstinent from
tobacco smoking.
▸ Dual use of e-cigarettes with tobacco cigarettes did not
encourage quitting tobacco or e-cigarette use, but may be
helpful to reduce tobacco consumption.
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